Dymon Asia Capital Singapore PTE. LTD. Makes New Investment in Zai Lab Limited (NASDAQ:ZLAB)

Dymon Asia Capital Singapore PTE. LTD. acquired a new position in shares of Zai Lab Limited (NASDAQ:ZLAB - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 20,000 shares of the company's stock, valued at approximately $524,000.

A number of other institutional investors have also added to or reduced their stakes in ZLAB. FMR LLC lifted its holdings in shares of Zai Lab by 749.1% during the fourth quarter. FMR LLC now owns 5,475,505 shares of the company's stock worth $143,403,000 after purchasing an additional 4,830,646 shares during the period. Clearbridge Investments LLC boosted its stake in Zai Lab by 113.3% during the fourth quarter. Clearbridge Investments LLC now owns 1,862,842 shares of the company's stock worth $48,788,000 after acquiring an additional 989,664 shares in the last quarter. Principal Financial Group Inc. acquired a new position in Zai Lab during the 4th quarter worth approximately $46,172,000. Allianz Asset Management GmbH grew its position in Zai Lab by 188.6% in the 4th quarter. Allianz Asset Management GmbH now owns 1,505,866 shares of the company's stock valued at $39,442,000 after purchasing an additional 984,041 shares during the period. Finally, ADAR1 Capital Management LLC raised its holdings in shares of Zai Lab by 96.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,045,837 shares of the company's stock worth $27,390,000 after acquiring an additional 513,383 shares during the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZLAB has been the subject of a number of recent research reports. Bank of America reiterated a "neutral" rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank initiated coverage on shares of Zai Lab in a research note on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target for the company. Finally, JPMorgan Chase & Co. raised their target price on shares of Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, March 13th.

Remove Ads

Insider Activity

In related news, CEO Ying Du sold 50,000 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $34.47, for a total transaction of $1,723,500.00. Following the completion of the sale, the chief executive officer now owns 494,117 shares of the company's stock, valued at approximately $17,032,212.99. This represents a 9.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Frazor Titus Edmondson III sold 14,544 shares of the business's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $32.98, for a total transaction of $479,661.12. Following the completion of the transaction, the insider now owns 14,328 shares in the company, valued at $472,537.44. The trade was a 50.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 138,744 shares of company stock valued at $4,685,294 in the last quarter. 13.88% of the stock is currently owned by company insiders.

Zai Lab Price Performance

Shares of Zai Lab stock traded down $0.95 during trading hours on Wednesday, reaching $29.43. The company's stock had a trading volume of 657,802 shares, compared to its average volume of 832,967. Zai Lab Limited has a one year low of $13.48 and a one year high of $39.77. The stock has a market cap of $3.23 billion, a P/E ratio of -10.62 and a beta of 1.09. The firm has a 50 day moving average price of $32.88 and a 200-day moving average price of $29.18.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.19). The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. As a group, sell-side analysts forecast that Zai Lab Limited will post -2.58 EPS for the current fiscal year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.